Clozapine prescribing during follow-up of a first-episode psychosis cohort

INTRODUCTION: Of those with schizophrenia, one third develop treatment-resistant illness. Nearly 60% of these benefit from clozapine- the only antipsychotic medication licensed in this group. OBJECTIVES: As treatment-resistant illness developed in the follow-up of a first-episode psychosis (FEP) coh...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowntree, R., Fanning, F., Keating, D., Murray, S., Szigeti, A., Doyle, R., Mcwilliams, S., Clarke, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479901/
http://dx.doi.org/10.1192/j.eurpsy.2021.2124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479901/
http://dx.doi.org/10.1192/j.eurpsy.2021.2124

Ejemplares similares